News

Postsurgical ctDNA is Associated With Recurrence in Metastatic Colorectal Cancer

05/19/2026

Emily Estrada

Results from a prospective study suggest that ctDNA dynamics may help stratify recurrence risk in patients with liver-limited metastatic colorectal cancer undergoing liver resection after upfront chemotherapy.

Results from a prospective study...

05/19/2026

Oncology

News

Etrumadenant-Based Chemoimmunotherapy Improves Survival in Metastatic Colorectal Cancer

04/01/2026

Emily Estrada

Results from the phase 2 ARC-9 study, demonstrate that etrumadenant plus zimberelimab, mFOLFOX-6, and bevacizumab significantly improves survival in heavily pretreated patients with metastatic colorectal cancer.

Results from the phase 2 ARC-9...

04/01/2026

Oncology

FDA Approval

FDA Grants Traditional Approval to Encorafenib-Cetuximab Plus Chemotherapy for BRAF V600E-Mutant Metastatic Colorectal Cancer

02/24/2026

Gina Tomaine

On February 24, 2026, the FDA granted traditional approval to frontline encorafenib in combination with cetuximab and fluorouracil-based chemotherapy for patients with metastatic colorectal cancer harboring a BRAF V600E mutation, as detected...

On February 24, 2026, the FDA...

02/24/2026

Oncology

Conference Coverage

Encorafenib and Cetuximab Plus FOLFIRI Demonstrates Superior Response Rates for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer

01/12/2026

Emily Estrada

In the BREAKWATER trial, first-line treatment with encorafenib plus cetuximab and FOLFIRI improved response rates compared to standard chemotherapy for BRAF V600E-mutant metastatic colorectal cancer, with manageable toxicity.

In the BREAKWATER trial,...

01/12/2026

Oncology

Conference Coverage

Encorafenib and Cetuximab Plus FOLFIRI Demonstrates Superior Response Rates for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer

01/12/2026

Emily Estrada

In the BREAKWATER trial,...

01/12/2026

Oncology

News

Circulating Tumor DNA-Guided Cetuximab Rechallenge Shows Improved Outcomes for Select Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer

01/12/2026

Emily Estrada

Data from the CAVE-2 GOIM trial demonstrated the benefit of comprehensive molecular stratification to predict the efficacy of anti-EGFR drug rechallenge strategies for certain patients with RAS/BRAF wild-type metastatic colorectal cancer.

Data from the CAVE-2 GOIM trial...

01/12/2026

Oncology

News

CMS4 Identified as Potential Biomarker of Anti-EGFR Benefit in RAS/BRAF Wild-Type Metastatic Colorectal Cancer

12/16/2025

Stephanie Holland

According to results from an individual patient data meta-analysis, CMS4 may serve as a predictive biomarker for improved outcomes with anti-EGFR therapy among patients with RAS and BRAF wild-type metastatic colorectal cancer.

According to results from an...

12/16/2025

Oncology

News

Plasma Tie2 Predicts Bevacizumab Response in Patients With Metastatic Colorectal Cancer

12/03/2025

Stephanie Holland

New long-term data from the phase 2 TRAVASTIN study reinforce plasma Tie2 as a meaningful vascular response biomarker for bevacizumab among patients with metastatic colorectal cancer (mCRC).

New long-term data from the...

12/03/2025

Oncology

News

Panitumumab Retreatment Improves Outcomes in RAS/BRAF Wild-Type Metastatic Colorectal Cancer

11/12/2025

Stephanie Holland

Panitumumab retreatment showed improved response and disease control compared to regorafenib among patients with chemorefractory RAS and BRAF wild-type metastatic colorectal cancer who exhibited no mutations of resistance in ctDNA.

Panitumumab retreatment showed...

11/12/2025

Oncology

News

Eribulin Demonstrates Limited Efficacy in BRAF V600E-Mutated Metastatic Colorectal Cancer

11/04/2025

Stephanie Holland

Results from the phase 2 BRAVERY trial show that eribulin demonstrates limited efficacy in previously treated patients with BRAF V600E-mutated metastatic colorectal cancer.

Results from the phase 2 BRAVERY...

11/04/2025

Oncology

Recent News

News

Tafasitamab Plus Lenalidomide and R-CHOP Significantly Improves PFS in High-Risk Diffuse Large B-Cell Lymphoma or High-Grade B-Cell Lymphoma

09/21/2026

Emily Estrada

Results from the phase 3 FrontMIND trial demonstrated that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in previously untreated patients with high-risk diffuse large B-cell lymphoma or...

Results from the phase 3...

09/21/2026

Oncology

FDA Approval

FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer

09/18/2026

Stephanie Holland

Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...

Based on results from the phase...

09/18/2026

Oncology

FDA Alerts

FDA Approves Taletrectinib Label Update Reflecting Durable Responses in TKI-Naïve ROS1-Positive Non-Small Cell Lung Cancer

09/17/2026

Emily Estrada

The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...

The FDA approved a supplemental...

09/17/2026

Oncology

News

Epcoritamab Plus Lenalidomide and Rituximab Shows Superior Efficacy in Second-Line or Later Follicular Lymphoma

09/17/2026

Emily Estrada

Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...

Results from the phase 3 EPCORE...

09/17/2026

Oncology

News

Low-Dose Ruxolitinib Significantly Reduces Acute Graft-Versus-Host Disease After Haploidentical Transplantation

09/17/2026

Emily Estrada

Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...

Results from a phase 3 trial...

09/17/2026

Oncology

News

Sacituzumab Govitecan Plus Pembrolizumab Fails to Significantly Improve PFS in PD-L1–High Metastatic Non-Small Cell Lung Cancer

09/16/2026

Stephanie Holland

Results from the phase 3 EVOKE-03 trial demonstrated that adding sacituzumab govitecan to pembrolizumab did not significantly improve progression-free or overall survival in untreated patients with PD-L1–high metastatic non-small cell lung...

Results from the phase 3...

09/16/2026

Oncology

FDA Alerts

FDA Label Update Shortens Initial Tarlatamab Monitoring to Support Broader Extensive-Stage Small Cell Lung Cancer Treatment Access

09/16/2026

Stephanie Holland

The FDA updated the prescribing information for tarlatamab to substantially shorten monitoring following the first 2 doses in patients with extensive-stage small cell lung cancer, potentially reducing treatment burden and facilitating...

The FDA updated the prescribing...

09/16/2026

Oncology

News

Tarlatamab Plus Durvalumab Improves Survival as First-Line Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer

09/15/2026

Emily Estrada

Topline results from the phase 3 DeLLphi-305 trial showed that adding tarlatamab to durvalumab significantly improved overall and progression-free survival compared with durvalumab alone as first-line maintenance therapy for patients with...

Topline results from the phase 3...

09/15/2026

Oncology

News

GLP-1 Receptor Agonists Linked to Lower Mortality and Thrombotic Complications in Essential Thrombocythemia

09/15/2026

Emily Estrada

Real-world findings associated GLP-1 receptor agonist use with improved survival and lower rates of thrombotic, cardiovascular, and infectious complications among patients with essential thrombocythemia, supporting prospective investigation...

Real-world findings associated...

09/15/2026

Oncology

News

Sustained Ropeginterferon Alfa-2b Treatment Deepens Molecular Responses in High-Risk Essential Thrombocythemia

09/15/2026

Emily Estrada

Extended results from the phase 3 SURPASS-ET trial showed that ropeginterferon alfa-2b provided durable hematologic responses and progressively reduced JAK2 V617F variant allele frequency in patients with high-risk essential thrombocythemia,...

Extended results from the phase...

09/15/2026

Oncology